HealthWarehouse.com (HEWA) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	7-May-15
Document And Entity Information
Entity Registrant Name	HealthWarehouse.com, Inc.
Entity Central Index Key	754813
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		37,570,383
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$265,848	$506,019
Restricted cash	195,088	195,088
Accounts receivable, net of allowance of $47,143 and $47,233 as of March 31, 2015 and December 31, 2014, repectively	112,354	100,886
Inventories - finished goods, net	145,270	144,236
Prepaid expenses and other current assets	47,345	60,202
Total current assets	765,905	1,006,431
Property and equipment, net of accumulated depreciation of $720,228 and $692,903 as of March 31, 2015 and December 31, 2014	489,499	511,286
Web development costs, net of accumulated amortization of $88,882 and $70,498 as of March 31, 2015 and December 31, 2014	135,148	142,541
Total assets	1,390,552	1,660,258
Current liabilities:
Accounts payable - trade	2,411,287	2,542,938
Accounts payable - related parties	83,932	84,314
Accrued expenses and other current liabilities	405,747	680,506
Deferred revenue	5,643	7,009
Current portion of equipment lease payable	65,513	64,101
Notes payable and other advances, net of debt discount of $45,150 and $58,367 as of March 31, 2015 and December 31, 2014, respectively	804,850	791,633
Note payable and other advances - related parties	73,095	73,095
Redeemable preferred stock - Series C; par value $0.001 per share; 10,000 designated Series C: 10,000 issued and outstanding as of March 31, 2015 and December 31, 2014 (aggregate liquidation preference of $1,000,000)	1,000,000	1,000,000
Total current liabilities	4,850,067	5,243,596
Long term liabilities:
Long term portion of equipment lease payable	29,349	46,143
Total long term liabilities	29,349	46,143
Total liabilities	4,879,416	5,289,739
Commitments and contingencies
Preferred stock - par value $0.001 per share; authorized 1,000,000 shares; issued and outstanding as of March 31, 2015 and December 31, 2014 as follows:
Convertible preferred stock - Series A - 200,000 shares designated Series A; 44,443 shares available to be issued; no shares issued and outstanding
Convertible preferred stock - Series B - 625,000 shares designated Series B; 483,512 and 451,879 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively (aggregate liquidation preference of $4,649,149 and $4,569,175 as of March 31, 2015 and December 31, 2014, respectively)	483	452
Common stock - par value $0.001 per share; authorized 100,000,000 shares; 38,749,595 shares issued and 37,570,383 shares outstanding as of March 31, 2015 and December 31, 2014.	38,751	38,751
Additional paid-in capital	30,385,231	29,966,039
Employee advances		-2,143
Treasury stock, at cost, 1,179,212 shares as of March 31, 2015 and December 31, 2014	-3,419,715	-3,419,715
Accumulated deficit	-30,493,614	-30,212,865
Total stockholders' deficiency	-3,488,864	-3,629,481
Total liabilities and stockholders' deficiency	$1,390,552	$1,660,258

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Accounts receivable, net of allowance	$47,143	$47,233
Property and equipment, net of accumulated depreciation	720,228	692,903
Web development costs, net of accumulated amortization	88,882	70,498
Current liabilities:
Current portion of notes payable, net of debt discount	45,150	58,367
Redeemable preferred stock Series C, par value	0.001	0.001
Redeemable preferred stock Series C, shares designated	10,000	10,000
Redeemable preferred stock Series C, shares issued	10,000	10,000
Redeemable preferred stock Series C, shares outstanding	10,000	10,000
Redeemable preferred stock Series C, aggregate liquidation preference	1,000,000	1,000,000
Stockholders' deficiency:
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	1,000,000	1,000,000
Series A Convertible preferred stock, shares designated	200,000	200,000
Series A Convertible preferred stock, shares available to be issued	44,443	44,443
Series A Convertible preferred stock, shares issued	0	0
Series A Convertible preferred stock, shares outstanding	0	0
Series B Convertible preferred stock, shares designated	625,000	625,000
Series B Convertible preferred stock, shares issued	483,512	451,879
Series B Convertible preferred stock, shares outstanding	483,512	451,879
Series B Convertible preferred stock, aggregate liquidation preference	$4,649,149	$4,569,175
Common stock, par value	$0.00	$0.00
Common stock, authorized	100,000,000	100,000,000
Common stock, shares issued	38,749,595	38,749,595
Common stock, shares outstanding	37,570,383	37,570,383
Treasury stock, shares	1,179,212	1,179,212

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Consolidated Statements Of Operations
Net sales	$1,612,677	$1,716,964
Cost of sales	631,163	731,408
Gross profit	981,514	985,556
Operating expenses:
Selling, general and administrative expenses	1,107,550	1,217,661
Loss from operations	-126,036	-232,105
Other income (expense):
Interest expense	-74,752	-73,536
Total other expense	-74,752	-73,536
Net loss	-200,788	-305,641
Series B convertible contractual dividends	-79,961	-74,730
Loss attributable to common stockholders	($280,749)	($380,371)
Per share data:
Net loss - basic and diluted	($0.01)	($0.01)
Series B convertible contractual dividends	$0	$0
Net loss attributable to common stockholders - basic and diluted	($0.01)	($0.01)
Weighted average number of common shares outstanding - basic and diluted	37,570,383	26,546,832

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Cash flows from operating activities
Net loss	($200,788)	($305,641)	($1,783,279)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	90	-41,458
Provision for employee advance reserve	2,143	-1,714
Depreciation and amortization	45,661	41,621
Stock-based compensation	79,005	162,763
Gain on settlement of accounts payable	-66,179	-64,597
Imputed value of services contributed		87,500
Amortization of debt discount	54,517	54,035
Changes in operating assets and liabilities:
Accounts receivable	-11,558	273,902
Inventories - finished goods	-1,034	31,149
Prepaid expenses and other current assets	12,857	18,531
Accounts payable - trade	-65,472	-318,734
Accounts payable - related parties	-382	-5,445
Accrued expenses and other current liabilities	-55,802	25,172
Deferred revenue	-1,366	-17,002
Net cash used in operating activities	-208,308	-59,918	-875,769
Cash flows from investing activities
Capital expenditures	-5,539
Website development costs	-10,942	-34,866
Net cash used in investing activities	-16,481	-34,866
Cash flows from financing activities
Principal payments on equipment leases payable	-15,382	-13,159
Proceeds from issuance of notes payable		100,000
Net cash (used in) provided by financing activities	-15,382	86,841
Net decrease in cash	-240,171	-7,944
Cash - beginning of period	506,019	67,744	67,744
Cash - end of period	265,848	59,800	506,019
Cash paid for:
Interest	19,544	25,523
Non-cash investing and financing activities:
Issuance of Series B preferred stock for settlement of accrued dividends	298,918	279,380
Warrants issued as debt discount in connection with notes payable	41,300	26,000
Accrual of contractual dividends on Series B convertible preferred stock	$79,961	$74,730

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
1. Organization and Basis of Presentation	HealthWarehouse.com, Inc., a Delaware company incorporated in 1998, (the “Company”) is a U.S. licensed virtual retail pharmacy (“VRP”) and healthcare e-commerce company that sells brand name and generic prescription drugs as well as over-the-counter (“OTC”) medical products. The Company’s objective is to be viewed by individual healthcare product consumers as a low-cost, reliable and hassle-free provider of prescription drugs and OTC medical products. The Company is presently licensed as a mail-order pharmacy for sales to 50 states in the United States and the District of Columbia.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of March 31, 2015 and for the three months ended March 31, 2015 and 2014. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full year ending December 31, 2015 or any other period. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related disclosures of the Company as of December 31, 2014 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 30, 2015.

Going_Concern_and_Managements_

Going Concern and Management's Liquidity Plans	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
2. Going Concern and Management's Liquidity Plans	Since inception, the Company has financed its operations primarily through debt and equity financings and advances from related parties. As of March 31, 2015, the Company had a working capital deficiency of $4,084,162 and an accumulated deficit of $30,493,614. During the three months ended March 31, 2015 and the year ended December 31, 2014, the Company incurred net losses of $200,788 and $1,783,279, respectively and used cash in operating activities of $208,308 and $875,769, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	Subsequent to March 31, 2015, the Company continues to incur net losses, use cash in operating activities and experience cash and working capital constraints.
	On February 13, 2013, the Company received a Notice of Redemption related to its Series C Redeemable Preferred Stock aggregating $1,000,000 (see Note 6). As a result of receiving the Notice of Redemption, the Company must now apply all of its assets to redemption of the Series C Preferred Stock and to no other corporate purpose, except to the extent prohibited by Delaware law governing distributions to stockholders (the Company is not permitted to utilize toward the redemption those assets required to pay its debts as they come due and those assets required to continue as a going concern).
	The Company recognizes it will need to raise additional capital in order to fund operations, meet its payment obligations and execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, attempt to extend note repayments, attempt to negotiate the preferred stock redemption and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. If the Company is unable to obtain financing on a timely basis, the Company could be forced to sell its assets, discontinue its operation and /or seek reorganization under the U.S. bankruptcy code.
	Accordingly, the accompanying condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the condensed consolidated financial statements do not necessarily represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
3. Summary of Significant Accounting Policies	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of HealthWarehouse.com, Inc., Hwareh.com, Inc., Hocks.com, Inc., ION Holding NV and ION Belgium NV, its wholly-owned subsidiaries. ION Holding NV and ION Belgium NV are inactive subsidiaries. All material inter-company balances and transactions have been eliminated in consolidation.
	On June 4, 2013, the Company formed a wholly-owned subsidiary called Pagosa Health LLC (“Pagosa”). On January 14, 2014, the Company closed Pagosa and decided to focus on its core consumer prescription business. Pagosa was dissolved in July 2014.
	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s significant estimates include reserves related to accounts receivable and inventory, the recoverability and useful lives of long-lived assets, the valuation allowance related to deferred tax assets, the valuation of equity instruments and debt discounts.
	Net Earnings (Loss) Per Share of Common Stock
	Basic net earnings (loss) per share is computed by dividing net earnings (loss) attributable to Common Stockholders by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share reflects the potential dilution that could occur if securities or other instruments to issue Common Stock were exercised or converted into Common Stock. Potentially dilutive securities are excluded from the computation of diluted net earnings (loss) per share if their inclusion would be anti-dilutive and consist of the following:
		March 31,
		2015		2014
	Options		3,944,557		2,514,150
	Warrants		9,839,044		2,492,846
	Series B Convertible Preferred Stock		5,507,202		3,714,445
	Total potentially dilutive shares		19,290,803		8,721,441
	Recently Issued Accounting Pronouncements
	The Company has determined there are no new accounting standards that are expected to have a material impact on the Company's condensed consolidated financial statements.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
4. Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following:
		March 31,		December 31,
		2015		2014
	Deferred Rent	$	33,503	$	36,053
	Advertising		76,639		109,930
	Salaries and Benefits		80,597		82,222
	Customer Payables		297		635
	Dividend Payable		79,961		298,918
	Accrued Interest		49,681		48,868
	Accrued Rent		47,942		46,604
	Other		37,127		57,276
	Total	$	405,747	$	680,506

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
5. Notes Payable	The Company is a party to a Loan and Security Agreement (the “Loan Agreement”) with a lender (the "Lender"). Under the terms of the Loan Agreement, the Company borrowed an aggregate of $750,000 from the Lender (the “Loan”). The Loan is evidenced by a promissory note (the “Senior Note”) in the face amount of $750,000 (as amended). Effective March 1, 2015, near the original maturity date, the Lender agreed to extend the maturity date of the Senior Note from March 1, 2015 to September 1, 2015 and agreed to extend the maturity date for an additional six months to March 1, 2016 if the Company meets certain financial requirements. The Senior Note bears interest on the unpaid principal balance of the Note until the full amount of principal has been paid at a floating rate equal to the Prime Rate plus four and one-quarter percent (4.25%) per annum (7.50% as of March 31, 2015). Under the terms of the Loan Agreement, the Company has agreed to make monthly payments of accrued interest on the first day of every month. The principal amount and all unpaid accrued interest on the Note is payable on September 1, 2015, or earlier in the event of default or a sale or liquidation of the Company. The Loan may be prepaid in whole or in part at any time by the Company without penalty. The Senior Note contains financial covenants which require the Company to meet certain minimum targets for earnings before interest, taxes and non-cash expenses, including depreciation, amortization and stock-based compensation (“EBITDAS”). The Company granted the Lender a first, priority security interest in all of the Company’s assets, in order to secure the Company’s obligation to repay the Loan, including a Deposit Account Control Agreement, which grants the Lender a security interest in certain bank accounts.
	In connection with the extension of the maturity date of the Senior Note, the Company granted the Lender five-year warrants to purchase 500,000 shares of Common Stock at an exercise price of $0.10 per share. The warrants had a relative fair value of $41,300 using the Black-Scholes model (see Note 6) which was established as debt discount during the three months ended March 31, 2015 and will be amortized using the effective interest method over the remaining term of the Senior Note. Including the value of warrants issued in connection with extension of the maturity date of the Senior Note, the Note had an effective interest rate of 19% per annum.
	The Company recorded amortization of debt discount associated with notes payable of $54,517 and $54,035 for the three months ended March 31, 2015 and 2014, respectively.

Stockholders_Deficiency

Stockholders' Deficiency	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
6. Stockholders' Deficiency	Preferred Stock
	As of March 31, 2015 and December 31, 2014, the Company had accrued contractual dividends of $79,961 and $298,918, respectively, related to the Series B Preferred Stock. On January 1, 2015 and 2014, the Company issued 31,633 and 29,564 shares of Series B convertible preferred stock valued at approximately $299,000 and $279,000, respectively, representing approximately $0.66 in value per share of Series B Preferred Stock outstanding on each date, to the Series B convertible preferred stock owners as payment in kind for dividends.
	Stock Options
	Stock-based compensation expense related to stock options was recorded in the condensed consolidated statements of operations as a component of selling, general and administrative expenses and totaled $78,789 and $151,853 for the three months ended March 31, 2015 and 2014, respectively.
	As of March 31, 2015, stock-based compensation expense related to stock options of $1,060,043 remains unamortized, including $168,474 which is being amortized over the weighted average remaining period of 1.0 years. The remaining $891,569 is related to a performance based option where vesting is currently deemed to be improbable and no amount is being amortized.
	Warrants
	Valuation
	In applying the Black-Scholes option pricing model to stock warrants, the Company used the following weighted average assumptions:
		For The Three Months Ended
		March 31,
		2015			2014
	Risk free interest rate		1.5	%		1.74	%
	Dividend yield		0	%		0	%
	Expected volatility		196	%		171	%
	Expected life in years		5			5
	Grants
	The weighted average fair value of the stock warrants granted during the three months ended March 31, 2015 and 2014, was $0.08 and $0.23 per share, respectively.
	Stock-based compensation expense related to warrants for the three months ended March 31, 2015 and 2014 was recorded in the condensed consolidated statements of operations as a component of selling, general and administrative expenses and totaled $216 and $264, respectively. As of March 31, 2015, stock-based compensation expense related to warrants of $577,307 remains unamortized, including $467 which is being amortized over the weighted average remaining period of 0.5 years. The remaining $576,840 is related to a performance based warrant where vesting is currently deemed to be improbable and no amount is being amortized.
	A summary of the stock warrant activity during the three months ended March 31, 2015 is presented below:
					Weighted			Average
					Average			Remaining			Aggregate
		Number of			Exercise			Life			Intrinsic
		Warrants			Price			In Years			Value
	Outstanding, January 1, 2015		9,339,044		$	0.45
	Granted		500,000		$	0.1
	Exercised		-		$	-
	Forfeited		-			-
	Outstanding, March 31, 2015		9,839,044		$	0.44			4		$	-
	Exercisable, March 31, 2015		9,579,044		$	0.37			4.1		$	-
	The following table presents information related to stock warrants at March 31, 2015:
			Warrants Outstanding						Warrants Exercisable
			Weighted						Weighted			Weighted
	Range of		Average			Outstanding			Average			Average		Exercisable
	Exercise		Exercise			Number of			Exercise			Remaining Life		Number of
	Price		Price			Warrants			Price			In Years		Warrants
	$0.10 - $0.35		$	0.27			9,246,198		$	0.27			4.2		9,246,198
	$0.36 - $3.00			2.91			562,846			2.91			1.4		312,846
	$3.01 - $4.95			4.95			30,000			4.95			2.5		20,000
	$0.10 - $4.95		$	0.44			9,839,044		$	0.37			4.1		9,579,044

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
7. Commitments and Contingent Liabilities	Operating Leases
	The Company is a party to a lease agreement for approximately 62,000 square feet of office and storage space with an entity. The monthly lease rate is $10,671 for 2015 and $11,975 in year 2016. The Company accounts for rent expense using the straight line method of accounting, deferring the difference between actual rent due and the straight line amount. The lease expires on January 1, 2017. Deferred rent payable of $33,503 and $36,053 as of March 31, 2015 and December 31, 2014, respectively, has been included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.
	On June 7, 2013, Pagosa signed a three year lease for $1,000 per month to house an office, pharmacy as well as inventory and is located in Lawrenceburg, IN. On July 8, 2013, the parties agreed to extend the lease for two additional years, such that the new termination date is now June 7, 2018. On January 14, 2014, the Company closed Pagosa Health and vacated the Lawrenceburg facility. The Company is currently in discussions with the Landlord regarding termination of the lease related to the building. The present value of the remaining lease payments of $47,942 is reflected as a component of accrued expenses and other liabilities on the condensed consolidated financial statements as of March 31, 2015.
	On December 15, 2014, the Company entered into a sublease agreement for 34,106 square feet of warehouse space at the Company’s corporate headquarters in Florence, Kentucky. The initial term of the sublease expires on June 14, 2015 with rent of $9,948 per month. After the expiration of the initial term, the tenant may extend the term of the sublease agreement on a month to month basis.
	Future minimum payments, by year and in the aggregate, under operating leases as of March 31, 2015 are as follows:
	For years ending December 31,	Amount
	2015	$	105,039
	2016		155,700
	2017		12,000
	2018		5,000
	Total future minimum lease payments	$	277,739
	During the three months ended March 31, 2015 and 2014, the Company recorded aggregate rent expense of $18,342 (net of sub-lease) and $49,229, respectively.
	Litigation
	In the ordinary course of business, we may become subject to lawsuits and other claims and proceedings that might arise from litigation matters or regulatory audits. Such matters are subject to uncertainty and outcomes are often not predictable with assurance. Our management does not presently expect that any such matters will have a material adverse effect on the Company’s condensed consolidated financial condition or condensed consolidated results of operations. We are not currently involved in any pending or threatened material litigation or other material legal proceedings nor have we been made aware of any penalties from regulatory audits.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
8. Concentrations	During the three months ended March 31, 2015, two vendors represented 74% and 10% of total inventory purchases. During the three months ended March 31, 2014, two vendors represented 57% and 16% of total inventory purchases, respectively.
	One vendor represented 38% and 36% of the accounts payable balance as of March 31, 2015 and December 31, 2014, respectively.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
9. Related Party Transactions	Effective September 4, 2014, the Company entered into a Consulting Agreement with a stockholder to provide consulting services related to business development and marketing activities for the Company and other duties as agreed to by management. The Company is required to pay the related party a monthly fee of $10,000 plus expense reimbursement. Subsequent to the effective date, the related party agreed to defer the payment of the monthly fee for a period of four months beginning with the November 4, 2014 payment. The deferred fees will be payable on the earlier of the termination date or the second anniversary of the effective date. The Consulting Agreement has an initial term of one year and can be automatically renewed for a one year period unless terminated by either party. The Agreement may be terminated by the Company by providing a sixty day notice prior to the first anniversary of the effective date. During the three months ended March 31, 2015, the Company incurred consulting and other expenses of $30,000 related to the Consulting Agreement.
	Between June 2009 and April 2012, an employee who is the son of the managing member of a limited liability company that beneficially owns over 5% of the Company’s Common Stock received advances from the Company in various forms which totaled $391,469 including interest. Principal repayments towards the outstanding advances aggregating $235,000 have been made through March 31, 2014. In April 2012, this employee voluntarily resigned from the Company. The individual agreed to repay the remaining balance with interest based on prime rate on the first business day of the calendar quarter. The amount has been included in Stockholders’ Deficiency as the Company has determined to exercise its rights through a pledge agreement for 42,860 shares as collateral. At December 31, 2014, the Company estimated the value of the collateral at $2,143. During the three months ended March 31, 2015, the Company wrote off the value of the collateral to $0.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
10. Subsequent Events	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.
	Stock Option Grants
	On April 3, 2015, the Company granted options to employees of the Company to purchase an aggregate of 922,223 shares of common stock under the 2014 Plan at an exercise price of $0.09 per share for an aggregate grant date value of $81,419. The options have a vesting period ranging from immediate to three years and have a term of ten years.
	On April 3, 2015, the Company granted options to consultants of the Company to purchase an aggregate of 149,861 shares of common stock under the 2014 Plan at an exercise price of $0.09 per share for an aggregate grant date value of $13,462. The options vested on the grant date and have a term of ten years.
	On April 7, 2015, the Company granted options to directors of the Company to purchase an aggregate of 102,189 shares of common stock under the 2014 Plan at an exercise price of between $0.09 per share for an aggregate grant date value of $9,000. The options vested on the grant date and have a term of ten years. The options were granted as part of director compensation approved by the Compensation Committee.
	Warrant Grants
	On April 3, 2015, the Company granted warrants to a former employee of the Company to purchase an aggregate of 137,430 shares of common stock under the 2014 Plan at an exercise price of $0.09 per share for an aggregate grant date value of $12,018. The warrants have a term of five years. The warrants were issued as repayment for amounts previously accrued.
	Amendment to Lease Agreement
	On April 27, 2015, the Company entered in an amendment to the lease agreement related to the Florence, KY location. The amendment reduced the square feet of office and storage space from approximately 62,000 to approximately 28,500 square feet, effective June 15, 2015. Per the amendment, the monthly lease rate will reduce to $7,770 in June 2015, $4,868 for the remainder of 2015 and $5,462 in year 2016.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Summary Of Significant Accounting Policies Policies
Principles of Consolidation	The condensed consolidated financial statements include the accounts of HealthWarehouse.com, Inc., Hwareh.com, Inc., Hocks.com, Inc., ION Holding NV and ION Belgium NV, its wholly-owned subsidiaries. ION Holding NV and ION Belgium NV are inactive subsidiaries. All material inter-company balances and transactions have been eliminated in consolidation.
	On June 4, 2013, the Company formed a wholly-owned subsidiary called Pagosa Health LLC (“Pagosa”). On January 14, 2014, the Company closed Pagosa and decided to focus on its core consumer prescription business. Pagosa was dissolved in July 2014.
Use of Estimates	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s significant estimates include reserves related to accounts receivable and inventory, the recoverability and useful lives of long-lived assets, the valuation allowance related to deferred tax assets, the valuation of equity instruments and debt discounts.
Net Earnings (Loss) Per Share of Common Stock	Basic net earnings (loss) per share is computed by dividing net earnings (loss) attributable to Common Stockholders by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share reflects the potential dilution that could occur if securities or other instruments to issue Common Stock were exercised or converted into Common Stock. Potentially dilutive securities are excluded from the computation of diluted net earnings (loss) per share if their inclusion would be anti-dilutive and consist of the following:
		March 31,
		2015		2014
	Options		3,944,557		2,514,150
	Warrants		9,839,044		2,492,846
	Series B Convertible Preferred Stock		5,507,202		3,714,445
	Total potentially dilutive shares		19,290,803		8,721,441
Recently Issued Accounting Pronouncements	The Company has determined there are no new accounting standards that are expected to have a material impact on the Company's condensed consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Summary Of Significant Accounting Policies Tables
Schedule of Potentially Dilutive Securities		March 31,
		2015		2014
	Options		3,944,557		2,514,150
	Warrants		9,839,044		2,492,846
	Series B Convertible Preferred Stock		5,507,202		3,714,445
	Total potentially dilutive shares		19,290,803		8,721,441

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Expenses And Other Current Liabilities Tables
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities consisted of the following:
		March 31,		December 31,
		2015		2014
	Deferred Rent	$	33,503	$	36,053
	Advertising		76,639		109,930
	Salaries and Benefits		80,597		82,222
	Customer Payables		297		635
	Dividend Payable		79,961		298,918
	Accrued Interest		49,681		48,868
	Accrued Rent		47,942		46,604
	Other		37,127		57,276
	Total	$	405,747	$	680,506

Stockholders_Deficiency_Tables

Stockholders' Deficiency (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders Deficiency Tables
Schedule of Stock Warrants Granted	In applying the Black-Scholes option pricing model to stock warrants, the Company used the following weighted average assumptions:
		For The Three Months Ended
		March 31,
		2015			2014
	Risk free interest rate		1.5	%		1.74	%
	Dividend yield		0	%		0	%
	Expected volatility		196	%		171	%
	Expected life in years		5			5
Summary of Stock Warrant Activity	A summary of the stock warrant activity during the three months ended March 31, 2015 is presented below:
					Weighted			Average
					Average			Remaining			Aggregate
		Number of			Exercise			Life			Intrinsic
		Warrants			Price			In Years			Value
	Outstanding, January 1, 2015		9,339,044		$	0.45
	Granted		500,000		$	0.1
	Exercised		-		$	-
	Forfeited		-			-
	Outstanding, March 31, 2015		9,839,044		$	0.44			4		$	-
	Exercisable, March 31, 2015		9,579,044		$	0.37			4.1		$	-
Summary of Stock Warrants Outstanding and Exercisable	The following table presents information related to stock warrants at March 31, 2015:
			Warrants Outstanding						Warrants Exercisable
			Weighted						Weighted			Weighted
	Range of		Average			Outstanding			Average			Average		Exercisable
	Exercise		Exercise			Number of			Exercise			Remaining Life		Number of
	Price		Price			Warrants			Price			In Years		Warrants
	$0.10 - $0.35		$	0.27			9,246,198		$	0.27			4.2		9,246,198
	$0.36 - $3.00			2.91			562,846			2.91			1.4		312,846
	$3.01 - $4.95			4.95			30,000			4.95			2.5		20,000
	$0.10 - $4.95		$	0.44			9,839,044		$	0.37			4.1		9,579,044

Commitments_and_Contingent_Lia1

Commitments and Contingent Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments And Contingent Liabilities Tables
Summary of future minimum payments under operating leases	Future minimum payments, by year and in the aggregate, under operating leases as of March 31, 2015 are as follows:
	For years ending December 31,	Amount
	2015	$	105,039
	2016		155,700
	2017		12,000
	2018		5,000
	Total future minimum lease payments	$	277,739

Going_Concern_and_Managements_1

Going Concern and Management's Liquidity Plans (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Going Concern And Managements Liquidity Plans Details Narrative
Working Capital Deficiency	$4,084,162
Accumulated deficit	30,493,614		30,212,865
Net Losses	-200,788	-305,641	-1,783,279
Net Cash Used in Operating Activities	($208,308)	($59,918)	($875,769)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Summary Of Significant Accounting Policies Details
Options	$3,944,557	$2,514,150
Warrants	9,839,044	2,492,846
Series B Convertible Preferred Stock	5,507,202	3,714,445
Total potentially dilutive shares	$19,290,803	$8,721,441

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued Expenses And Other Current Liabilities Details
Deferred rent	$33,503	$36,053
Advertising	76,639	109,930
Salaries and benefits	80,597	82,222
Customer payables	297	635
Dividends payable	79,961	298,918
Accrued interest	49,681	48,868
Accrued Rent	47,942	46,604
Other	37,127	57,276
Total	$405,747	$680,506

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Notes Payable Details Narrative
Interest rate of Senior Note	7.50%
Aggregate number of warrants issued	500,000
Warrants issued exercise price	$0.10
Fair value related to warrants as debt discount	$41,300
Amortization of the debt discount	54,517	54,035
Total borrowing amount of loan	$750,000

Stockholders_Deficiency_Detail

Stockholders' Deficiency (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stockholders Deficiency Details
Risk free interest rate	1.50%	1.74%
Dividend yield	0.00%	0.00%
Expected volatility	196.00%	171.00%
Expected life in years	5 years	5 years

Stockholders_Deficiency_Detail1

Stockholders' Deficiency (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015
Number of warrants, outstanding
Outstanding, beginning of period (in shares)	9,339,044
Granted	500,000
Exercised
Forfeited
Outstanding, end of period (in shares)	9,839,044
Exercisable, March 31, 2015	9,579,044
Weighted average exercise price
Outstanding, beginning of period (in dollars per share)	$0.45
Granted	$0.10
Exercised
Forfeited
Outstanding, end of period (in dollars per share)	$0.44
Exercisable, March 31, 2015	$0.37
Weighted Average Remaining Life In Years
Weighted Average Remaining Life (in years) Outstanding	4 years
Weighted Average Remaining Life (in years) Exercisable	4 years 1 month 6 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding
Aggregate Intrinsic Value Exercisable, March 31, 2015

Stockholders_Deficiency_Detail2

Stockholders' Deficiency (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Weighted Average Exercise Price Outstanding	$0.44	$0.45
Number Outstanding	9,839,044	9,339,044
Number Exercisable	9,579,044
$0.10 - $0.35 | Warrant [Member]
Weighted Average Exercise Price Outstanding	$0.27
Number Outstanding	9,246,198
Weighted Average Exercise Price Exercisable	$0.27
Weighted Average Remaining Years of Contractual Life	4 years 2 months 12 days
Number Exercisable	9,246,198
$0.36 - $3.00 | Warrant [Member]
Weighted Average Exercise Price Outstanding	$2.91
Number Outstanding	562,846
Weighted Average Exercise Price Exercisable	$2.91
Weighted Average Remaining Years of Contractual Life	1 year 4 months 24 days
Number Exercisable	312,846
$3.01 - $4.95 | Warrant [Member]
Weighted Average Exercise Price Outstanding	$4.95
Number Outstanding	30,000
Weighted Average Exercise Price Exercisable	$4.95
Weighted Average Remaining Years of Contractual Life	2 years 6 months
Number Exercisable	20,000
$0.10 - $4.95 | Warrant [Member]
Weighted Average Exercise Price Outstanding	$0.44
Number Outstanding	9,839,044
Weighted Average Exercise Price Exercisable	$0.37
Weighted Average Remaining Years of Contractual Life	4 years 1 month 6 days
Number Exercisable	9,579,044

Stockholders_Deficiency_Detail3

Stockholders' Deficiency (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Stock Warrants [Member]
Weighted Average Fair Value	$0.08	$0.23
Selling, General And Administrative Expenses	$216	$264
Stock-based compensation expense, unamortized	577,307
Stock-Based Compensation Expense, amortized	467
Weighted Average Remaining Period	6 months
Performance based option vesting	576,840
Series B Preferred Stock [Member]
Preferred Stock Contractual Dividends	79,961		298,918
Stock Option [Member]
Selling, General And Administrative Expenses	78,789	151,853
Stock-based compensation expense, unamortized	1,060,043
Stock-Based Compensation Expense, amortized	168,474
Weighted Average Remaining Period	1 year
Performance based option vesting	$891,569

Commitments_and_Contingent_Lia2

Commitments and Contingent Liabilities (Details 1) (USD $)	Mar. 31, 2015
Commitments And Contingent Liabilities Details 1
2015	$105,039
2016	155,700
2017	12,000
2018	5,000
Total future minimum lease payments	$277,739

Commitments_and_Contingent_Lia3

Commitments and Contingent Liabilities (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Commitments And Contingent Liabilities Details Narrative
Deferred rent payable	$33,503		$36,053
Lease payments	47,942
Rent Expense	18,342	49,229
Monthly lease rate in 2015	10,671
Monthly lease rate in 2016	$11,975

Concentrations_Details_Narrati

Concentrations (Details Narrative)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Vendor 1 [Member]
Concentration Inventory Purchases Percentage	74.00%	57.00%
Concentration Accounts Payable Percentage	38.00%		36.00%
Vendor 2 [Member]
Concentration Inventory Purchases Percentage	10.00%	16.00%

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Related Party Transactions Details Narrative
Consulting and other expenses	$30,000
Estimated the value of collateral	0		2,143
Principal repayments towards the outstanding advances		$235,000